Research and Markets: Global HER2-Negative Breast Cancer Market 2015-2019

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/8pm5bx/global) has announced the addition of the "Global HER2-Negative Breast Cancer Market 2015-2019" report to their offering.

The global HER2-negative breast cancer market is forecast to grow at a CAGR of 15.94% over the period 2014-2019.

The report, Global HER2-Negative Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global HER2-negative breast cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

This report covers the present scenario and the growth prospects of the global HER2-negative breast cancer market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of HER2-negative breast cancer.

An increase in the patient assistance programs by government organizations and vendors will also boost the market growth. These programs are customized to meet the needs of patients who are unable to afford the expensive therapies.

According to the report, the market is expected to grow because of the significant unmet medical needs across the globe. There has been a growth in the demand for various drugs to treat and prevent HER2-negative breast cancer progression. The present therapies also exhibit several safety issues, which decreases patient compliance. This presents an opportunity for drug makers to develop a therapy that can treat the cancer with better efficacy and safety parameters.

Further, the report states that the market growth may be hampered because of the use of premium-priced therapies. The drugs used to treat HER2-negative breast cancer, including biologic therapies, are expensive. This could lead to treatment withdrawal by patients.

Based on type of drug molecule, the market is segmented as follows:

- Biologics

- Small molecules

Based on route of administration, the market is segmented as follows:

- Oral

- Parenteral

Key vendors

- F. Hoffmann-La Roche

- Novartis

- Pfizer

Other prominent vendors

- AbbVie

- AstraZeneca

- BioMarin

- Bristol-Myers Squibb

- Eisai

- Eli Lilly

- Galena Biopharma

- Incyte

- Merck

- Merck Serono

- Merrimack

- Nektar

- Tesaro

For more information visit http://www.researchandmarkets.com/research/8pm5bx/global

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women's Health, Breast Cancer

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women's Health, Breast Cancer